Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The complement-dendritic cell-endothelial cell crosstalk in vascular inflammation.

Cardiovascular research·2025
Same author

Special Issue: "Post-COVID-19 Syndrome".

Viruses·2025
Same author

Priv.-Doz. Dr. med. Rainer B. Zotz.

Hamostaseologie·2023
Same author

Post-COVID Syndrome in Adults-An Overview.

Viruses·2023
Same author

Cardiac Arrhythmias in Post-COVID Syndrome: Prevalence, Pathology, Diagnosis, and Treatment.

Viruses·2023
Same author

Early SARS-CoV-2 infection: Platelet-neutrophil complexes and platelet function.

Research and practice in thrombosis and haemostasis·2022
Same journal

Gut Microbiome-Associated Thrombosis: Approaching Validation?

Seminars in thrombosis and hemostasis·2026
Same journal

Bridging the Gap in Laboratory Monitoring of Extended Half-Life Factor VIII and IX: Can Thrombin Generation Assays Overcome Assay Discrepancies?

Seminars in thrombosis and hemostasis·2026
Same journal

External Quality Assessment for Low Molecular Weight Heparin Monitoring in the Australasia/Asia-Pacific Region.

Seminars in thrombosis and hemostasis·2026
Same journal

Human evolution: between hemorrhage and thrombosis.

Seminars in thrombosis and hemostasis·2026
Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
See all related articles

Related Experiment Video

Updated: May 17, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Drugs that affect platelet function.

Rüdiger E Scharf1

  • 1Department of Clinical and Experimental Hemostasis, Hemotherapy and Transfusion Medicine, Hemophilia Comprehensive Care Center, Heinrich Heine University, Düsseldorf, Germany. rscharf@uni-duesseldorf.de

Seminars in Thrombosis and Hemostasis
|November 1, 2012
PubMed
Summary
This summary is machine-generated.

Many common medications, not just antiplatelet drugs, can impair platelet function, increasing bleeding risk. Identifying patients with pre-existing bleeding disorders is crucial for preventing complications.

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Experiment Videos

Last Updated: May 17, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Area of Science:

  • Pharmacology
  • Hematology
  • Internal Medicine

Background:

  • Drug-induced platelet dysfunction is a significant clinical concern, contributing to bleeding diathesis.
  • While antiplatelet agents are known culprits, numerous other commonly prescribed medications can also affect platelet function.
  • Patients with underlying hemostatic defects are particularly vulnerable to pharmacologically induced bleeding complications.

Purpose of the Study:

  • To review a wide range of medications that interfere with platelet function, beyond traditional antiplatelet drugs.
  • To detail the mechanisms and drug interactions leading to drug-induced platelet dysfunction.
  • To emphasize the importance of identifying patients at risk for bleeding due to medication effects.

Main Methods:

  • Literature review of scientific articles and clinical studies.
  • Analysis of drug mechanisms affecting platelet reactivity.
  • Examination of clinical implications of drug-induced platelet dysfunction.

Main Results:

  • A broad spectrum of drugs, including NSAIDs, antibiotics, cardiovascular drugs, and SSRIs, can impair platelet function.
  • These agents can cause or exacerbate bleeding, especially in patients with pre-existing hemostatic defects.
  • Understanding these effects is vital for preventing unexpected hemorrhages and managing patient care.

Conclusions:

  • Pharmacologically induced platelet dysfunction is a widespread issue with significant clinical implications.
  • Identification of patients susceptible to bleeding complications from non-antiplatelet medications is essential.
  • Awareness of these drug effects aids in risk mitigation, adequate symptom management, and optimized patient care.